Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Novel immunotherapy clinical trials in malignant pleural mesothelioma.

Tano ZE, Chintala NK, Li X, Adusumilli PS.

Ann Transl Med. 2017 Jun;5(11):245. doi: 10.21037/atm.2017.03.81.

2.

Lung cancer: Biology and treatment options.

Lemjabbar-Alaoui H, Hassan OU, Yang YW, Buchanan P.

Biochim Biophys Acta. 2015 Dec;1856(2):189-210. doi: 10.1016/j.bbcan.2015.08.002. Epub 2015 Aug 19. Review.

3.

Switching off malignant pleural effusion formation-fantasy or future?

Spella M, Giannou AD, Stathopoulos GT.

J Thorac Dis. 2015 Jun;7(6):1009-20. doi: 10.3978/j.issn.2072-1439.2015.05.20. Review.

4.

Brain Tumor Immunotherapy: What have We Learned so Far?

Van Gool SW.

Front Oncol. 2015 Jun 17;5:98. doi: 10.3389/fonc.2015.00098. eCollection 2015. Review.

5.

Surgical cytoreduction restores the antitumor efficacy of a Listeria monocytogenes vaccine in malignant pleural mesothelioma.

Kennedy GT, Judy BF, Bhojnagarwala P, Moon EK, Fridlender ZG, Albelda SM, Singhal S.

Immunol Lett. 2015 Jul;166(1):28-35. doi: 10.1016/j.imlet.2015.05.009. Epub 2015 May 18.

6.

Immunotherapy prospects in the treatment of lung cancer and mesothelioma.

Aerts JG, Lievense LA, Hoogsteden HC, Hegmans JP.

Transl Lung Cancer Res. 2014 Feb;3(1):34-45. doi: 10.3978/j.issn.2218-6751.2013.11.04. Review.

7.

New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials.

Kotova S, Wong RM, Cameron RB.

Cancer Manag Res. 2015 Jan 23;7:51-63. doi: 10.2147/CMAR.S72814. eCollection 2015. Review.

8.

Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

van Zandwijk N, Clarke C, Henderson D, Musk AW, Fong K, Nowak A, Loneragan R, McCaughan B, Boyer M, Feigen M, Currow D, Schofield P, Nick Pavlakis BI, McLean J, Marshall H, Leong S, Keena V, Penman A.

J Thorac Dis. 2013 Dec;5(6):E254-307. doi: 10.3978/j.issn.2072-1439.2013.11.28. Review. No abstract available.

9.

Tumour-derived exosomes as antigen delivery carriers in dendritic cell-based immunotherapy for malignant mesothelioma.

Mahaweni NM, Kaijen-Lambers ME, Dekkers J, Aerts JG, Hegmans JP.

J Extracell Vesicles. 2013 Oct 24;2. doi: 10.3402/jev.v2i0.22492. eCollection 2013.

10.

Immunological profiling as a means to invigorate personalized cancer therapy.

Hegmans JP, Aerts JG.

Oncoimmunology. 2013 Aug 1;2(8):e25236. Epub 2013 Jun 10.

11.

Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid.

Scherpereel A, Grigoriu BD, Noppen M, Gey T, Chahine B, Baldacci S, Trauet J, Copin MC, Dessaint JP, Porte H, Labalette M.

BMC Cancer. 2013 Jul 2;13:324. doi: 10.1186/1471-2407-13-324.

12.

New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas.

Mossman BT, Shukla A, Heintz NH, Verschraegen CF, Thomas A, Hassan R.

Am J Pathol. 2013 Apr;182(4):1065-77. doi: 10.1016/j.ajpath.2012.12.028. Epub 2013 Feb 8. Review.

13.

Improving lung cancer survival; time to move on.

Heuvers ME, Hegmans JP, Stricker BH, Aerts JG.

BMC Pulm Med. 2012 Dec 13;12:77. doi: 10.1186/1471-2466-12-77.

14.

Trial watch: Dendritic cell-based interventions for cancer therapy.

Galluzzi L, Senovilla L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G.

Oncoimmunology. 2012 Oct 1;1(7):1111-1134.

15.

New roads open up for implementing immunotherapy in mesothelioma.

Cornelissen R, Heuvers ME, Maat AP, Hendriks RW, Hoogsteden HC, Aerts JG, Hegmans JP.

Clin Dev Immunol. 2012;2012:927240. doi: 10.1155/2012/927240. Epub 2012 Jun 24. Review.

16.

Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.

Bograd AJ, Suzuki K, Vertes E, Colovos C, Morales EA, Sadelain M, Adusumilli PS.

Cancer Immunol Immunother. 2011 Nov;60(11):1509-27. doi: 10.1007/s00262-011-1103-6. Epub 2011 Sep 13. Review.

17.

Update in lung cancer and oncological disorders 2010.

Halmos B, Powell CA.

Am J Respir Crit Care Med. 2011 Aug 1;184(3):297-302. doi: 10.1164/rccm.201103-0370UP. No abstract available.

18.

Specific microtubule-depolymerizing agents augment efficacy of dendritic cell-based cancer vaccines.

Wen CC, Chen HM, Chen SS, Huang LT, Chang WT, Wei WC, Chou LC, Arulselvan P, Wu JB, Kuo SC, Yang NS.

J Biomed Sci. 2011 Jun 20;18:44. doi: 10.1186/1423-0127-18-44.

19.

What's the place of immunotherapy in malignant mesothelioma treatments?

Grégoire M.

Cell Adh Migr. 2010 Jan-Mar;4(1):153-61. Epub 2010 Jan 30. Review.

Supplemental Content

Support Center